Wednesday, December 20, 2017 7:56:14 PM
https://www.nice.org.uk/guidance/indevelopment/gid-hst10009/consultation/html-content
Don't know why anyone is surprised if NICE didn't initially recommend Vertex's CF drugs there was no way they would recommend Scenesse especially if the company is sticking to the "uniform pricing" nonsense. Since they apparently have limited bandwidth to pursue concurrent reimbursements this should have been (very) low on the priority unless they were open to price negotiations (the main objective of NICE). Just another dumb decision by management no surprise here.
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM